Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–84 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Arthritis, Juvenile Idiopathic Clear all
Completed Phase 2 Interventional Results available

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

NCT00130637
View directory record Official record
Conditions
Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 9, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Results available

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

NCT01904279
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Hartford, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 9, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

NCT03311854
View directory record Official record
Conditions
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
0 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 9, 2026, 2:03 AM EDT
Recruiting No phase listed Observational

Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.

NCT07845942
View directory record Official record
Conditions
Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis Associated Lung Disease
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 9, 2026, 2:03 AM EDT
Completed No phase listed Observational Results available

Start Time Optimization of Biologics in Polyarticular JIA

NCT02593006
View directory record Official record
Conditions
Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
52
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 9, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional Results available

Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA

NCT05710640
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Active tcVNS, Sham tcVNS
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 9, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

NCT02296424
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis (SJIA)
Interventions
ACZ885 150 mg (Canakinumab)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 20 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 9, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

NCT01904292
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 9, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study Of Tofacitinib In Pediatric JIA Population

NCT02592434
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550 (tofacitinib), placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 9, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 9, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

NCT02776735
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 9, 2026, 2:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis

NCT01434082
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
comparison of types of sleep disordered breathing
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
6 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Oct 9, 2026, 2:03 AM EDT